Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers

BACKGROUND: Treatment with apremilast has recently demonstrated clinically meaningful improvement in moderate hidradenitis suppurativa (HS). OBJECTIVE: To evaluate the change in expression of inflammatory markers in lesional skin of HS patients receiving apremilast 30 mg twice daily (n = 15) for 16 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Vossen, A.R.J.V., van der Zee, H.H., Davelaar, N., Mus, A.M.C., van Doorn, M.B.A., Prens, E.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acne ‐ Rosacea
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590194/
https://www.ncbi.nlm.nih.gov/pubmed/30451329
http://dx.doi.org/10.1111/jdv.15354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590194/
https://www.ncbi.nlm.nih.gov/pubmed/30451329
http://dx.doi.org/10.1111/jdv.15354

Ejemplares similares